Skip to main content

Advertisement

SpringerLink
Log in

Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

For women affected by breast cancer who carry germline BRCA1/2 pathogenic variants, the classic standard treatment consists of therapeutic unilateral mastectomy and risk-reducing contralateral mastectomy. However, data from recent literature demonstrate that for women treated with breast-conserving surgery who receive adequate adjuvant treatments, the increased risk of locoregional recurrences and a breast cancer-related prognosis is not significant. This review describes the clinical factors that could help clinicians decide either against or in favor of a more aggressive type of breast cancer surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Corso G, Robson ME, Sacchini V. Points to consider regarding risk-reducing mastectomy in high-, moderate-, and low-penetrance gene carriers. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11913-6.

    Article  PubMed  Google Scholar 

  2. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144:443–55.

    Article  CAS  PubMed  Google Scholar 

  3. Nelson JA, Rubenstein RN, Haglich K, et al. Analysis of a trend reversal in US lumpectomy rates from 2005 through 2017 using 3 nationwide data sets. JAMA Surg. 2022;157:702–11.

    Article  PubMed  Google Scholar 

  4. Morrow M. Surgery and prophylactic surgery in hereditary breast cancer. Breast. 2022;62(Suppl 1):S63–6.

    Article  PubMed  Google Scholar 

  5. Corso G, Magnoni F. Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations. Eur J Cancer Prev. 2021;30:311–4.

    Article  PubMed  Google Scholar 

  6. Burstein HJ, Curigliano G, Loibl S, et al. Members of the St.Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St.Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–57.

    Article  CAS  PubMed  Google Scholar 

  7. Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, et al. Breast cancer risk genes: association analysis in more than 113,000 women. N Engl J Med. 2021;384:428–39.

    Article  Google Scholar 

  8. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887–92.

    Article  PubMed  Google Scholar 

  9. Poehls UG, Hack CC, Wunderle M, et al. Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years. Eur J Cancer Prev. 2019;28:515–21.

    Article  CAS  PubMed  Google Scholar 

  10. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165:193–200.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–99.

    Article  Google Scholar 

  12. Corso G, Feroce I, Intra M, et al. BRCA1/2 germline missense mutations: a systematic review. Eur J Cancer Prev. 2018;27:279–86.

    Article  CAS  PubMed  Google Scholar 

  13. Shimelis H, Mesman RLS, Von Nicolai C, et al. BRCA2 Hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. 2017;77:2789–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Li H, Engel C, de la Hoya M, et al. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genet Med. 2022;24:119–29.

    Article  PubMed  Google Scholar 

  15. Girardi A, Magnoni F, Vicini E, et al. CDH1 germline mutations in families with hereditary lobular breast cancer. Eur J Cancer Prev. 2022;31:274–8.

    Article  CAS  PubMed  Google Scholar 

  16. Yadav S, Hu C, Nathanson KL, et al. Germline pathogenic variants in cancer predisposition genes among women with invasive lobular carcinoma of the breast. J Clin Oncol. 2021;39:3918–26.

    Article  CAS  PubMed  Google Scholar 

  17. Jones EG. Familial gastric cancer. N Z Med J. 1964;63:287–96.

    CAS  PubMed  Google Scholar 

  18. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.

    Article  CAS  PubMed  Google Scholar 

  19. Campbell I, Scott N, Seneviratne S, et al. Breast cancer characteristics and survival differences between Maori, Pacific, and other New Zealand women included in the Quality Audit Program of Breast Surgeons of Australia and New Zealand. Asian Pac J Cancer Prev. 2015;16:2465–72.

    Article  PubMed  Google Scholar 

  20. Corso G, Corso F, Bellerba F, et al. Geographical distribution of E-cadherin germline mutations in the context of diffuse gastric cancer: a systematic review. Cancers Basel. 2021;13:1269.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Keinan-Boker L, Baron-Epel O, Fishler Y, et al. Breast cancer trends in Israeli Jewish and Arab women, 1996–2007. Eur J Cancer Prev. 2013;22:112–20.

    Article  PubMed  Google Scholar 

  22. Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996;347:1643–5.

    Article  CAS  PubMed  Google Scholar 

  23. Robson M, Dabney MK, Rosenthal G, et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test. 1997;1:47–51.

    Article  CAS  PubMed  Google Scholar 

  24. Kauff ND, Perez-Segura P, Robson ME, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high-risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002;39:611–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rennert G, Dishon S, Rennert HS, Fares F. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel. Eur J Cancer Prev. 2005;14:357–61.

    Article  CAS  PubMed  Google Scholar 

  26. Zhang Y, Wu H, Yu Z, et al. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients. BMC Cancer. 2022;22:842.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kuschel B, Lux MP, Goecke TO, Beckmann MW. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev. 2000;9:139–50.

    Article  CAS  PubMed  Google Scholar 

  28. Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31:3091–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Shubeck S, Sevilimedu V, Berger E, Robson M, Heerdt AS, Pilewskie ML. Comparison of outcomes between BRCA pathogenic variant carriers undergoing breast-conserving surgery versus mastectomy. Ann Surg Oncol. 2022;29:4706–13.

    Article  PubMed  Google Scholar 

  30. Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: a nationwide cohort study. Breast. 2022;61:98–107.

    Article  PubMed  Google Scholar 

  31. Vaz-Luis I, Masiero M, Cavaletti G, et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol. 2022. https://doi.org/10.1016/j.annonc.2022.07.1941.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This study was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 × 1000 funds.

Author information

Authors and Affiliations

  1. Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy

    Giovanni Corso MD, PhD, Francesca Magnoni MD, PhD & Paolo Veronesi MD

  2. Department of Oncology and Hemato-Oncology, Faculty of Medicine, University of Milan, Milan, Italy

    Giovanni Corso MD, PhD & Paolo Veronesi MD

  3. European Cancer Prevention Organization, Milan, Italy

    Giovanni Corso MD, PhD

Authors
  1. Giovanni Corso MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Magnoni MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Veronesi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Corso MD, PhD.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corso, G., Magnoni, F. & Veronesi, P. Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer. Ann Surg Oncol 29, 8084–8089 (2022). https://doi.org/10.1245/s10434-022-12542-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12542-9

Search

Navigation